LAKELAND INDUSTRIES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LAKELAND INDUSTRIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $192.65M | Apr 16, 2026 |
| FY2026 | Jan 31, 2025 | $167.21M | Apr 16, 2026 |
| FY2023 | Apr 30, 2024 | $6.30M | Apr 18, 2023 |
| FY2025 | Jan 31, 2024 | $124.69M | Apr 17, 2025 |
| FY2023 | Apr 30, 2023 | $6.00M | Apr 18, 2023 |
| FY2024 | Jan 31, 2023 | $112.85M | Apr 11, 2024 |
| FY2023 | Jan 31, 2022 | $118.39M | Apr 18, 2023 |
| FY2022 | Jan 31, 2021 | $159.00M | Apr 21, 2022 |
| FY2021 | Jan 31, 2020 | $107.81M | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $99.01M | Apr 15, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $63.33M | Apr 16, 2026 |
| FY2026 | Jan 31, 2025 | $68.67M | Apr 16, 2026 |
| FY2025 | Jan 31, 2024 | $51.19M | Apr 17, 2025 |
| FY2024 | Jan 31, 2023 | $45.85M | Apr 11, 2024 |
| FY2023 | Jan 31, 2022 | $50.91M | Apr 18, 2023 |
| FY2022 | Jan 31, 2021 | $79.28M | Apr 21, 2022 |
| FY2021 | Jan 31, 2020 | $37.90M | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $33.91M | Apr 15, 2020 |
| FY2018 | Jan 31, 2018 | $9.90M | Apr 16, 2018 |
| FY2018 | Oct 31, 2017 | $9.05M | Apr 16, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | ($25.31M) | Apr 16, 2026 |
| FY2026 | Jan 31, 2025 | ($18.08M) | Apr 16, 2026 |
| FY2025 | Jan 31, 2024 | $5.43M | Apr 17, 2025 |
| FY2024 | Jan 31, 2023 | $1.87M | Apr 11, 2024 |
| FY2023 | Jan 31, 2022 | $11.37M | Apr 18, 2023 |
| FY2022 | Jan 31, 2021 | $35.33M | Apr 21, 2022 |
| FY2021 | Jan 31, 2020 | $3.28M | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $1.46M | Apr 15, 2020 |
| FY2019 | Jan 31, 2018 | $440.0K | Apr 16, 2019 |
| FY2018 | Jan 31, 2017 | $3.89M | Apr 16, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | ($15.51M) | Apr 16, 2026 |
| FY2026 | Jan 31, 2025 | ($9.27M) | Apr 16, 2026 |
| FY2025 | Jan 31, 2024 | $5.99M | Apr 17, 2025 |
| FY2024 | Jan 31, 2023 | $5.54M | Apr 11, 2024 |
| FY2023 | Jan 31, 2022 | $16.05M | Apr 18, 2023 |
| FY2022 | Jan 31, 2021 | $43.89M | Apr 21, 2022 |
| FY2021 | Jan 31, 2020 | $5.88M | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $3.57M | Apr 15, 2020 |
| FY2018 | Jan 31, 2018 | $1.16M | Apr 16, 2018 |
| FY2018 | Oct 31, 2017 | $2.67M | Apr 16, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Jan 31, 2021 | $200.0K | Apr 16, 2021 |
| FY2021 | Jan 31, 2020 | $200.0K | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $200.0K | Apr 15, 2020 |
| FY2019 | Jan 31, 2018 | $280.0K | Apr 16, 2019 |
| FY2018 | Jan 31, 2017 | $463.0K | Apr 16, 2018 |
| FY2018 | Jan 31, 2016 | $165.0K | Apr 16, 2018 |
| FY2016 | Jan 31, 2015 | $90.0K | Apr 21, 2016 |
| FY2015 | Jan 31, 2014 | $123.0K | May 18, 2015 |
| FY2013 | Jan 31, 2013 | $242.0K | Apr 28, 2014 |
| FY2012 | Jan 31, 2012 | $428.0K | Jul 16, 2013 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | ($15.75M) | Apr 16, 2026 |
| FY2026 | Jan 31, 2025 | ($15.88M) | Apr 16, 2026 |
| FY2025 | Jan 31, 2024 | $10.91M | Apr 17, 2025 |
| FY2024 | Jan 31, 2023 | ($5.45M) | Apr 11, 2024 |
| FY2023 | Jan 31, 2022 | $12.79M | Apr 18, 2023 |
| FY2022 | Jan 31, 2021 | $40.67M | Apr 21, 2022 |
| FY2021 | Jan 31, 2020 | $3.59M | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $1.79M | Apr 15, 2020 |
| FY2019 | Jan 31, 2018 | $648.0K | Apr 16, 2019 |
| FY2018 | Jan 31, 2017 | $11.49M | Apr 16, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $671.0K | Apr 16, 2026 |
| FY2026 | Jan 31, 2025 | $1.54M | Apr 16, 2026 |
| FY2025 | Jan 31, 2024 | $2.07M | Apr 17, 2025 |
| FY2024 | Jan 31, 2023 | $1.99M | Apr 11, 2024 |
| FY2023 | Jan 31, 2022 | $801.0K | Apr 18, 2023 |
| FY2022 | Jan 31, 2021 | $1.66M | Apr 21, 2022 |
| FY2021 | Jan 31, 2020 | $1.03M | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $3.10M | Apr 15, 2020 |
| FY2019 | Jan 31, 2018 | $905.0K | Apr 16, 2019 |
| FY2018 | Jan 31, 2017 | $413.0K | Apr 16, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $209.93M | Apr 16, 2026 |
| FY2026 | Jan 31, 2025 | $212.53M | Apr 16, 2026 |
| FY2025 | Jan 31, 2024 | $153.75M | Apr 17, 2025 |
| FY2024 | Jan 31, 2023 | $142.94M | Apr 11, 2024 |
| FY2023 | Jan 31, 2022 | $140.79M | Apr 18, 2023 |
| FY2022 | Jan 31, 2021 | $139.55M | Apr 21, 2022 |
| FY2021 | Jan 31, 2020 | $99.41M | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $94.72M | Apr 15, 2020 |
| FY2019 | Jan 31, 2018 | $94.53M | Apr 16, 2019 |
| FY2018 | Jan 31, 2017 | $84.55M | Apr 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $80.81M | Apr 16, 2026 |
| FY2026 | Jan 31, 2025 | $65.91M | Apr 16, 2026 |
| FY2025 | Jan 31, 2024 | $30.29M | Apr 17, 2025 |
| FY2024 | Jan 31, 2023 | $22.95M | Apr 11, 2024 |
| FY2023 | Jan 31, 2022 | $15.69M | Apr 18, 2023 |
| FY2022 | Jan 31, 2021 | $17.80M | Apr 21, 2022 |
| FY2021 | Jan 31, 2020 | $14.35M | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $11.50M | Apr 15, 2020 |
| FY2019 | Jan 31, 2018 | $11.69M | Apr 16, 2019 |
| FY2018 | Jan 31, 2017 | $13.05M | Apr 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $129.13M | Apr 16, 2026 |
| FY2026 | Jan 31, 2025 | $146.63M | Apr 16, 2026 |
| FY2026 | Jan 31, 2024 | $123.45M | Apr 16, 2026 |
| FY2025 | Jan 31, 2023 | $119.99M | Apr 17, 2025 |
| FY2024 | Jan 31, 2022 | $125.10M | Apr 11, 2024 |
| FY2023 | Jan 31, 2021 | $121.75M | Apr 18, 2023 |
| FY2022 | Jan 31, 2020 | $85.05M | Apr 21, 2022 |
| FY2021 | Jan 31, 2019 | $83.23M | Apr 16, 2021 |
| FY2020 | Jan 31, 2018 | $82.84M | Apr 15, 2020 |
| FY2019 | Jan 31, 2017 | $71.51M | Apr 16, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $15.29M | Apr 16, 2026 |
| FY2026 | Jan 31, 2025 | $16.24M | Apr 16, 2026 |
| FY2026 | Jan 31, 2024 | $13.67M | Apr 16, 2026 |
| FY2025 | Jan 31, 2023 | $8.47M | Apr 17, 2025 |
| FY2024 | Jan 31, 2022 | $871.0K | Apr 11, 2024 |
| FY2021 | Jan 31, 2021 | $871.0K | Apr 16, 2021 |
| FY2021 | Jan 31, 2020 | $871.0K | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $871.0K | Apr 15, 2020 |
| FY2019 | Jan 31, 2018 | $871.0K | Apr 16, 2019 |
| FY2018 | Jan 31, 2017 | $871.0K | Apr 16, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $23.86M | Apr 16, 2026 |
| FY2026 | Jan 31, 2025 | $50.32M | Apr 16, 2026 |
| FY2025 | Jan 31, 2024 | $69.28M | Apr 17, 2025 |
| FY2024 | Jan 31, 2023 | $64.77M | Apr 11, 2024 |
| FY2023 | Jan 31, 2022 | $62.89M | Apr 18, 2023 |
| FY2022 | Jan 31, 2021 | $51.52M | Apr 21, 2022 |
| FY2021 | Jan 31, 2020 | $17.58M | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $14.30M | Apr 15, 2020 |
| FY2019 | Jan 31, 2018 | $12.84M | Apr 16, 2019 |
| FY2018 | Jan 31, 2017 | $12.40M | Apr 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jan 31, 2024 | $25.22M | Apr 11, 2024 |
| FY2024 | Jan 31, 2023 | $24.64M | Apr 11, 2024 |
| FY2023 | Jan 31, 2022 | $52.72M | Apr 18, 2023 |
| FY2022 | Jan 31, 2021 | $52.60M | Apr 21, 2022 |
| FY2022 | Jan 31, 2020 | $14.61M | Apr 21, 2022 |
| FY2021 | Jan 31, 2019 | $12.83M | Apr 16, 2021 |
| FY2020 | Jan 31, 2018 | $15.79M | Apr 15, 2020 |
| FY2019 | Jan 31, 2017 | $10.37M | Apr 16, 2019 |
| FY2018 | Jan 31, 2016 | $7.02M | Apr 16, 2018 |
| FY2018 | Jan 31, 2015 | $6.71M | Apr 16, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $30.38M | Apr 16, 2026 |
| FY2026 | Jan 31, 2025 | $16.43M | Apr 16, 2026 |
| FY2020 | Jan 31, 2020 | $1.16M | Apr 15, 2020 |
| FY2019 | Jan 31, 2019 | $1.32M | Apr 16, 2019 |
| FY2018 | Jan 31, 2018 | $1.68M | Apr 16, 2018 |
| FY2017 | Jan 31, 2017 | $5.78M | Apr 26, 2017 |
| FY2016 | Jan 31, 2016 | $13.42M | Apr 21, 2016 |
| FY2015 | Jan 31, 2015 | $9.79M | May 18, 2015 |
| FY2013 | Jan 31, 2014 | $19.63M | Apr 28, 2014 |
| FY2012 | Jan 31, 2013 | $18.09M | Jul 16, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | (2) | Apr 16, 2026 |
| FY2026 | Jan 31, 2025 | (2) | Apr 16, 2026 |
| FY2025 | Jan 31, 2024 | 0 | Apr 17, 2025 |
| FY2024 | Jan 31, 2023 | 0 | Apr 11, 2024 |
| FY2023 | Jan 31, 2022 | 1 | Apr 18, 2023 |
| FY2022 | Jan 31, 2021 | 4 | Apr 21, 2022 |
| FY2021 | Jan 31, 2020 | 0 | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | 0 | Apr 15, 2020 |
| FY2019 | Jan 31, 2018 | 0 | Apr 16, 2019 |
| FY2017 | Jan 31, 2017 | 0 | Apr 26, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | (2) | Apr 16, 2026 |
| FY2026 | Jan 31, 2025 | (2) | Apr 16, 2026 |
| FY2025 | Jan 31, 2024 | 0 | Apr 17, 2025 |
| FY2024 | Jan 31, 2023 | 0 | Apr 11, 2024 |
| FY2023 | Jan 31, 2022 | 1 | Apr 18, 2023 |
| FY2022 | Jan 31, 2021 | 4 | Apr 21, 2022 |
| FY2021 | Jan 31, 2020 | 0 | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | 0 | Apr 15, 2020 |
| FY2019 | Jan 31, 2018 | 0 | Apr 16, 2019 |
| FY2017 | Jan 31, 2017 | 0 | Apr 26, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | 9.81M | Apr 16, 2026 |
| FY2026 | Jan 31, 2025 | 9.50M | Apr 16, 2026 |
| FY2025 | Jan 31, 2024 | 7.36M | Apr 17, 2025 |
| FY2024 | Jan 31, 2023 | 7.33M | Apr 11, 2024 |
| FY2023 | Jan 31, 2022 | 7.62M | Apr 18, 2023 |
| FY2022 | Jan 31, 2021 | 7.98M | Apr 21, 2022 |
| FY2021 | Jan 31, 2020 | 7.97M | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | 8.01M | Apr 15, 2020 |
| FY2019 | Jan 31, 2018 | 8.12M | Apr 16, 2019 |
| FY2018 | Jan 31, 2017 | 7.26M | Apr 16, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $1.15M | Apr 16, 2026 |
| FY2026 | Jan 31, 2025 | $887.0K | Apr 16, 2026 |
| FY2025 | Jan 31, 2024 | $908.0K | Apr 17, 2025 |